Neuroendocrine evaluation of central opiate activity in primary headache disorders

F. Facchinetti, E. Martignoni, V. Gallai, G. Micieli, F. Petraglia, G. Nappi, A. R. Genazzani

Research output: Contribution to journalArticle

Abstract

The evaluation of central opiate activity could be of clinical value in the diagnosis and treatment of pain syndromes. The current approach via direct measurement of endogenous opioid peptides in cerebrospinal fluid (CSF) is not devoid of side effects and cannot be used in every-day practice. As an alternative to this method, we have studied the neuroendocrine response of plasma LH to an i.v. naloxone injection in 39 headache sufferers from different diagnostic subgroups, and in 12 age- and sex-matched healthy volunteers. Patients (19 females and 20 males) were affected by common migraine (CM, 11 cases), migraine with interparoxysmal headache (MIH, 9), classical migraine (C1M, 9), and chronic cluster headache (CH, 10). Headache lasted 3-36 years. Prior to naloxone challenge (4 mg i.V.), LH pulsatility was evaluated for 1 h. The next morning, the pituitary response to LH-RH (10 μg i.v.) was tested in 20 patients. Plasma LH was measured by RIA in every sample. The response to the tests was evaluated as secretion area of plasma LH minus the mean basal value. Controls (497.5 ± 85.5 mIU/ml × 120 min), CIM (357.8 ± 78.9) and CH (450.5 ± 70.4) patients showed similar results, while in cases of CM (155.3 ± 71.7, P <0.05) and MIH (104.1 ± 53.7, P <0.01) the LH secretion after naloxone injection was significantly blunted. On the contrary, the response of LH to LH-RH was similar in controls and patient groups, thus excluding pituitary dysfunctions in this response. Given the fact that there are some limitations related to the modulatory effects of gonadal steroids, these data suggest the use of the naloxone test as a tool for exploring the central opiate activity in primary headache disorders, mainly in migraine syndromes. Indeed, the naloxone test fails in those diagnostic subgroups characterized by impaired CSF levels of endogenous opioids.

Original languageEnglish
Pages (from-to)29-33
Number of pages5
JournalPain
Volume34
Issue number1
DOIs
Publication statusPublished - 1988

Fingerprint

Opiate Alkaloids
Primary Headache Disorders
Naloxone
Headache
Migraine Disorders
Gonadotropin-Releasing Hormone
Cerebrospinal Fluid
Migraine without Aura
Cluster Headache
Migraine with Aura
Injections
Opioid Peptides
Opioid Analgesics
Healthy Volunteers
Steroids
Pain
Control Groups

Keywords

  • Headache
  • Migraine
  • Naloxone
  • Opiate activity

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neurology
  • Pharmacology
  • Clinical Psychology

Cite this

Facchinetti, F., Martignoni, E., Gallai, V., Micieli, G., Petraglia, F., Nappi, G., & Genazzani, A. R. (1988). Neuroendocrine evaluation of central opiate activity in primary headache disorders. Pain, 34(1), 29-33. https://doi.org/10.1016/0304-3959(88)90178-9

Neuroendocrine evaluation of central opiate activity in primary headache disorders. / Facchinetti, F.; Martignoni, E.; Gallai, V.; Micieli, G.; Petraglia, F.; Nappi, G.; Genazzani, A. R.

In: Pain, Vol. 34, No. 1, 1988, p. 29-33.

Research output: Contribution to journalArticle

Facchinetti, F, Martignoni, E, Gallai, V, Micieli, G, Petraglia, F, Nappi, G & Genazzani, AR 1988, 'Neuroendocrine evaluation of central opiate activity in primary headache disorders', Pain, vol. 34, no. 1, pp. 29-33. https://doi.org/10.1016/0304-3959(88)90178-9
Facchinetti, F. ; Martignoni, E. ; Gallai, V. ; Micieli, G. ; Petraglia, F. ; Nappi, G. ; Genazzani, A. R. / Neuroendocrine evaluation of central opiate activity in primary headache disorders. In: Pain. 1988 ; Vol. 34, No. 1. pp. 29-33.
@article{1191818593924ba88770b413cb650697,
title = "Neuroendocrine evaluation of central opiate activity in primary headache disorders",
abstract = "The evaluation of central opiate activity could be of clinical value in the diagnosis and treatment of pain syndromes. The current approach via direct measurement of endogenous opioid peptides in cerebrospinal fluid (CSF) is not devoid of side effects and cannot be used in every-day practice. As an alternative to this method, we have studied the neuroendocrine response of plasma LH to an i.v. naloxone injection in 39 headache sufferers from different diagnostic subgroups, and in 12 age- and sex-matched healthy volunteers. Patients (19 females and 20 males) were affected by common migraine (CM, 11 cases), migraine with interparoxysmal headache (MIH, 9), classical migraine (C1M, 9), and chronic cluster headache (CH, 10). Headache lasted 3-36 years. Prior to naloxone challenge (4 mg i.V.), LH pulsatility was evaluated for 1 h. The next morning, the pituitary response to LH-RH (10 μg i.v.) was tested in 20 patients. Plasma LH was measured by RIA in every sample. The response to the tests was evaluated as secretion area of plasma LH minus the mean basal value. Controls (497.5 ± 85.5 mIU/ml × 120 min), CIM (357.8 ± 78.9) and CH (450.5 ± 70.4) patients showed similar results, while in cases of CM (155.3 ± 71.7, P <0.05) and MIH (104.1 ± 53.7, P <0.01) the LH secretion after naloxone injection was significantly blunted. On the contrary, the response of LH to LH-RH was similar in controls and patient groups, thus excluding pituitary dysfunctions in this response. Given the fact that there are some limitations related to the modulatory effects of gonadal steroids, these data suggest the use of the naloxone test as a tool for exploring the central opiate activity in primary headache disorders, mainly in migraine syndromes. Indeed, the naloxone test fails in those diagnostic subgroups characterized by impaired CSF levels of endogenous opioids.",
keywords = "Headache, Migraine, Naloxone, Opiate activity",
author = "F. Facchinetti and E. Martignoni and V. Gallai and G. Micieli and F. Petraglia and G. Nappi and Genazzani, {A. R.}",
year = "1988",
doi = "10.1016/0304-3959(88)90178-9",
language = "English",
volume = "34",
pages = "29--33",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Neuroendocrine evaluation of central opiate activity in primary headache disorders

AU - Facchinetti, F.

AU - Martignoni, E.

AU - Gallai, V.

AU - Micieli, G.

AU - Petraglia, F.

AU - Nappi, G.

AU - Genazzani, A. R.

PY - 1988

Y1 - 1988

N2 - The evaluation of central opiate activity could be of clinical value in the diagnosis and treatment of pain syndromes. The current approach via direct measurement of endogenous opioid peptides in cerebrospinal fluid (CSF) is not devoid of side effects and cannot be used in every-day practice. As an alternative to this method, we have studied the neuroendocrine response of plasma LH to an i.v. naloxone injection in 39 headache sufferers from different diagnostic subgroups, and in 12 age- and sex-matched healthy volunteers. Patients (19 females and 20 males) were affected by common migraine (CM, 11 cases), migraine with interparoxysmal headache (MIH, 9), classical migraine (C1M, 9), and chronic cluster headache (CH, 10). Headache lasted 3-36 years. Prior to naloxone challenge (4 mg i.V.), LH pulsatility was evaluated for 1 h. The next morning, the pituitary response to LH-RH (10 μg i.v.) was tested in 20 patients. Plasma LH was measured by RIA in every sample. The response to the tests was evaluated as secretion area of plasma LH minus the mean basal value. Controls (497.5 ± 85.5 mIU/ml × 120 min), CIM (357.8 ± 78.9) and CH (450.5 ± 70.4) patients showed similar results, while in cases of CM (155.3 ± 71.7, P <0.05) and MIH (104.1 ± 53.7, P <0.01) the LH secretion after naloxone injection was significantly blunted. On the contrary, the response of LH to LH-RH was similar in controls and patient groups, thus excluding pituitary dysfunctions in this response. Given the fact that there are some limitations related to the modulatory effects of gonadal steroids, these data suggest the use of the naloxone test as a tool for exploring the central opiate activity in primary headache disorders, mainly in migraine syndromes. Indeed, the naloxone test fails in those diagnostic subgroups characterized by impaired CSF levels of endogenous opioids.

AB - The evaluation of central opiate activity could be of clinical value in the diagnosis and treatment of pain syndromes. The current approach via direct measurement of endogenous opioid peptides in cerebrospinal fluid (CSF) is not devoid of side effects and cannot be used in every-day practice. As an alternative to this method, we have studied the neuroendocrine response of plasma LH to an i.v. naloxone injection in 39 headache sufferers from different diagnostic subgroups, and in 12 age- and sex-matched healthy volunteers. Patients (19 females and 20 males) were affected by common migraine (CM, 11 cases), migraine with interparoxysmal headache (MIH, 9), classical migraine (C1M, 9), and chronic cluster headache (CH, 10). Headache lasted 3-36 years. Prior to naloxone challenge (4 mg i.V.), LH pulsatility was evaluated for 1 h. The next morning, the pituitary response to LH-RH (10 μg i.v.) was tested in 20 patients. Plasma LH was measured by RIA in every sample. The response to the tests was evaluated as secretion area of plasma LH minus the mean basal value. Controls (497.5 ± 85.5 mIU/ml × 120 min), CIM (357.8 ± 78.9) and CH (450.5 ± 70.4) patients showed similar results, while in cases of CM (155.3 ± 71.7, P <0.05) and MIH (104.1 ± 53.7, P <0.01) the LH secretion after naloxone injection was significantly blunted. On the contrary, the response of LH to LH-RH was similar in controls and patient groups, thus excluding pituitary dysfunctions in this response. Given the fact that there are some limitations related to the modulatory effects of gonadal steroids, these data suggest the use of the naloxone test as a tool for exploring the central opiate activity in primary headache disorders, mainly in migraine syndromes. Indeed, the naloxone test fails in those diagnostic subgroups characterized by impaired CSF levels of endogenous opioids.

KW - Headache

KW - Migraine

KW - Naloxone

KW - Opiate activity

UR - http://www.scopus.com/inward/record.url?scp=0023915580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023915580&partnerID=8YFLogxK

U2 - 10.1016/0304-3959(88)90178-9

DO - 10.1016/0304-3959(88)90178-9

M3 - Article

C2 - 3043318

AN - SCOPUS:0023915580

VL - 34

SP - 29

EP - 33

JO - Pain

JF - Pain

SN - 0304-3959

IS - 1

ER -